{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:15Z","timestamp":1786988115036,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejpb.2011.06.003","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T18:50:54Z","timestamp":1309027854000},"page":"646-657","source":"Crossref","is-referenced-by-count":29,"title":["Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation"],"prefix":"10.1016","volume":"79","author":[{"given":"Claudia","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinus A.H.","family":"Capelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor","family":"Arvinte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emek","family":"Seyrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Borchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2011.06.003_b0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nbt1108-1227","article-title":"What\u2019s fueling the biotech engine-2007","volume":"26","author":"Aggarwal","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nbt0407-380","article-title":"Billion dollar babies \u2013 biotech drugs as blockbusters","volume":"25","author":"Lawrence","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tibtech.2005.07.005","article-title":"Biopharmaceuticals: recent approvals and likely directions","volume":"23","author":"Walsh","year":"2005","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.06.003_b0025","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/jps.21566","article-title":"Protein aggregation: pathways, induction factors and analysis","volume":"98","author":"Mahler","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.06.003_b0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","article-title":"Formulation and manufacturability of biologics","volume":"20","author":"Shire","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0035","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/aic.11252","article-title":"Engineering challenges for protein formulations","volume":"53","author":"Randolph","year":"2007","journal-title":"Am. Inst. Chem. Eng. J."},{"key":"10.1016\/j.ejpb.2011.06.003_b0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.06.003_b0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/138920109788488932","article-title":"Mechanisms of protein aggregation","volume":"10","author":"Philo","year":"2009","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","article-title":"Protein aggregation \u2013 pathways and influencing factors","volume":"390","author":"Wang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.06.003_b0055","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1023\/A:1011974512425","article-title":"Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)","volume":"15","author":"Runkel","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.06.003_b0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/bc050322y","article-title":"Structure\u2013function engineering of interferon-\u03b2-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-pegylation","volume":"17","author":"Basu","year":"2006","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejpb.2011.06.003_b0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bc049781+","article-title":"Structural and biophysical characterization of the 40kDa PEG-interferon-\u03b12a and its individual positional isomers","volume":"16","author":"Dhalluin","year":"2005","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejpb.2011.06.003_b0070","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1110\/ps.052004006","article-title":"Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study","volume":"15","author":"Rajan","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejpb.2011.06.003_b0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2011.06.003_b0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2011.06.003_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0169-409X(93)90005-O","article-title":"The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential","volume":"10","author":"Katre","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2011.06.003_b0090","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.ddtec.2009.02.002","article-title":"PEGylation: posttranslational bioengineering of protein biotherapeutics","volume":"5","author":"Veronese","year":"2008","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ejpb.2011.06.003_b0095","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/jps.22401","article-title":"Non-covalent PEGylation as a new means against aggregation of salmon calcitonin","volume":"100","author":"Mueller","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.06.003_b0100","unstructured":"G. Borchard, C. Mueller, M.A.H. Capelle, T. Arvinte, Stabilized Protein Formulations and use thereof, Patent WO 2011\/051916 A2, 2011."},{"key":"10.1016\/j.ejpb.2011.06.003_b0105","unstructured":"FDA. <http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm092199.htm#T> (accessed on 02.09.10)."},{"key":"10.1016\/j.ejpb.2011.06.003_b0190","unstructured":"F. Veronese, Biologically active drug polymer derivatives and method for preparing same, Patent US005286637, 1994."},{"key":"10.1016\/j.ejpb.2011.06.003_b0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11095-008-9662-8","article-title":"A high throughput protein formulation platform: case study of salmon calcitonin","volume":"26","author":"Capelle","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.06.003_b0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbapap.2006.10.010","article-title":"Characterization of protein aggregation: the case of a therapeutic immunoglobulin","volume":"1774","author":"Demeule","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2011.06.003_b0125","series-title":"Principles of Fluorescence Spectroscopy","article-title":"Protein fluorescence","author":"Lakowicz","year":"2006"},{"key":"10.1016\/j.ejpb.2011.06.003_b0130","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1021\/ma00218a005","article-title":"Proton NMR characterization of poly(ethylene glycols) and derivatives","volume":"23","author":"Dust","year":"1990","journal-title":"Macromolecules"},{"key":"10.1016\/j.ejpb.2011.06.003_b0135","article-title":"1La and 1Lb transitions of tryptophan: applications of theory and experimental observations to fluorescence of proteins","volume":"vol. 278","author":"Callis","year":"1997"},{"key":"10.1016\/j.ejpb.2011.06.003_b0140","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/bi980274n","article-title":"Toward understanding tryptophan fluorescence in proteins","volume":"37","author":"Chen","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2011.06.003_b0145","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1021\/jp0310551","article-title":"Quantitative prediction of fluorescence quantum yields for tryptophan in proteins","volume":"108","author":"Callis","year":"2004","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejpb.2011.06.003_b0150","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.1021\/ja961307u","article-title":"The peptide bond quenches indole fluorescence","volume":"118","author":"Chen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2011.06.003_b0155","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1529\/biophysj.108.133025","article-title":"Molecular dynamics studies of polyethylene oxide and polyethylene glycol: hydrodynamic radius and shape anisotropy","volume":"95","author":"Lee","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2011.06.003_b0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11095-007-9516-9","article-title":"Extrinsic fluorescent dyes as tools for protein characterization","volume":"25","author":"Hawe","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.06.003_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10895-007-0156-6","article-title":"Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile Red","volume":"17","author":"Sutter","year":"2007","journal-title":"J. Fluorescence"},{"key":"10.1016\/j.ejpb.2011.06.003_b0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijpharm.2006.03.036","article-title":"Novel polymeric micelles for hydrophobic drug delivery based on biodegradable poly(hexyl-substituted lactides)","volume":"319","author":"Trimaille","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.06.003_b0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2011.06.003_b0180","first-page":"249","article-title":"Calculations of HLB values of nonionic surfactants","volume":"5","author":"Griffin","year":"1954","journal-title":"J. Soc. Cosmet. Chem."},{"key":"10.1016\/j.ejpb.2011.06.003_b0185","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/jp972436f","article-title":"Tryptophan fluorescence shifts in proteins from hybrid simulations: an electrostatic approach","volume":"101","author":"Callis","year":"1997","journal-title":"J. Phys. Chem. B"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T18:50:38Z","timestamp":1543690238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641111001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0939641111001779"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.06.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}